BioSpace News Archive

The projects include efficacy, safety and tolerance studies for new biomedical components, stem cell implants, dental implants, kidney transplants and the validation of latest-generation surgical robots like Bitrack, among others.

Halozyme Therapeutics, Inc. announced the appointment of Moni Miyashita to its board of directors.

Lonza has expanded its renowned human stem cell offerings to provide human cord blood CD34+ hematopoietic stem cells (CB-CD34+ HSCs) in large batch sizes, meeting a critical and rapidly expanding market need.

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the companies have submitted an application to the U.S. Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) of an additional booster dose adults 65 years of age and older who have received an initial booster of any of the authorized or approved COVID-19 vaccines.

Albany NY, United States: The blood group typing market is anticipated to flourish notably within the forecast period from 2017 to 2022.

Albany NY, United States: As per the reports by Transparency Market Research, the blood collection market is prognosticated to see a remarkable growth owing to the technological advancements and medical improvements in the field all over the world.

Santhera Pharmaceuticals and ReveraGen BioPharma, Inc announce presentations of efficacy and tolerability data with vamorolone in Duchenne muscular dystrophy at the 2022 Muscular Dystrophy Association Clinical & Scientific Conference.

RELIEF THERAPEUTICS Holding SA announced that its wholly owned subsidiary, APR Applied Pharma Research SA, has signed a binding term sheet with Meta Healthcare Ltd. to acquire the worldwide commercialization rights, except in the United Kingdom and Ireland, for a novel dosage form of a prescription drug already approved by the U.S. Food and Drug Administration and intended for the treatment of patients with phenylketonuria.

In February, just after the end of the quarter, we received feedback from the FDA, which means that we have a plan for our continued application process.

AlzeCure Pharma AB announced that the company’s presentation at the Alzheimer’s conference AD/PD 2022, on new clinical data with its lead drug candidate NeuroRestore ACD856, which is being developed with a focus on Alzheimer’s disease, is now available in its entirety on the company’s website.